Mark Gurman is a tech reporter for Bloomberg who has a long history of accurate reporting on Apple's product plans. With well over a decade of Apple coverage, his reports are closely watched due ...

If approved per MSD's filing, the new version would become an alternative to IV Keytruda for the full range of Keytruda indications, which span dozens of different cancers and treatment lines.